Treatment of functional dyspepsia with sertraline: A double-blind randomized placebo-controlled pilot study

Table 2 Dyspepsia index, 36-item short-form score and hospital anxiety scale results

	Week 0	P value	Week 4	P value	Week 8	P value
Mean dyspepsia score
Sertraline	25.83	0.124	22.59	0.740	20.53	0.02
Placebo	27.19		22.94		23.34
SF36-physical functioning
Sertraline	81.79	0.585	79.30	0.39	75.61	0.15
Placebo	83.11		81.63		80.39
SF36-role physical
Sertraline	57.91	0.30	52.62	0.40	52.70	0.22
Placebo	52.11		57.87		62.17
SF36-bodily pain
Sertraline	49.10	0.002	54.22	0.89	53.97	0.50
Placebo	41.06		53.78		51.63
SF36-general health
Sertraline	33.76		39.06		35.39
Placebo	32.54	0.65	41.85	0.34	34.72	0.84
SF36-vitality
Sertraline	47.69	0.57	47.91	0.73	49.05	0.68
Placebo	46.76		48.88		50.33
SF36-social function
Sertraline	67.75		72.38		68.41
Placebo	67.68	0.98	72.19	0.96	69.74	0.73
SF36-role emotional
Sertraline	51.82		53.49		52.70
Placebo	50.75	0.85	54.19	0.90	51.32	0.85
SF36-mental health
Sertraline	58.12		54.89		65.24
Placebo	58.59	0.83	61.57	0.03	64.37	0.69
HAD scale
Anxiety score
Sertraline	14.27	0.52	13.58		14.29
Placebo	13.88		13.66	0.90	13.68	0.41
HAD scale
Depression score
Sertraline	15.51	0.14	15.50	0.88	14.27	0.45
Placebo	14.84		15.56		13.70

HAD: Hospital Anxiety and Depression Scale; SF36: 36-item short-form.